Jennifer D Goldman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6997274/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Commentary: Why Was Inhaled Insulin a Failure in the Market?. Diabetes Spectrum, 2016, 29, 180-184.	0.4	54
2	New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus. Annals of Pharmacotherapy, 2015, 49, 1153-1161.	0.9	33
3	Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Current Medical Research and Opinion, 2017, 33, 1821-1831.	0.9	31
4	Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes. Diabetes Therapy, 2017, 8, 739-752.	1.2	29
5	Comparison of long-term knowledge retention in lecture-based versus flipped team-based learning course delivery. Currents in Pharmacy Teaching and Learning, 2017, 9, 391-397.	0.4	24
6	Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability. Journal of Pharmacy Technology, 2019, 35, 25-35.	0.5	17
7	Students' Attitudes, Academic Performance and Preferences for Content Delivery in a Very Large Self-Care Course Redesign. American Journal of Pharmaceutical Education, 2016, 80, 67.	0.7	16
8	Lixisenatide, a Onceâ€Daily Prandial Glucagonâ€Like Peptideâ€1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. Pharmacotherapy, 2017, 37, 927-943.	1.2	15
9	Performance and Perceptions of Student Teams Created and Stratified Based on Academic Abilities. American Journal of Pharmaceutical Education, 2017, 81, 47.	0.7	13
10	Transition of care to prevent recurrence after acute coronary syndrome: the critical role of the primary care provider and pharmacist. Postgraduate Medicine, 2020, 132, 426-432.	0.9	12
11	Insulin Degludec: A Novel Basal Insulin Analogue. Annals of Pharmacotherapy, 2013, 47, 269-277.	0.9	11
12	iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. Annals of Pharmacotherapy, 2017, 51, 990-999.	0.9	10
13	Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy. Clinical Medicine Insights: Endocrinology and Diabetes, 2018, 11, 117955141878625.	1.0	9
14	Cardiovascular safety outcomes of onceâ€weekly GLPâ€1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 61-72.	0.7	9
15	Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300ÂU/mL Who Participated in the COACH Support Program. Diabetes Therapy, 2018, 9, 2143-2153.	1.2	6
16	Human Regular 500 units/mL Insulin Therapy: A Review of Clinical Evidence and New Delivery Options. Clinical Diabetes, 2018, 36, 319-324.	1.2	5
17	Oral Superabsorbent Hydrogel (Plenity) for Weight Management. Annals of Pharmacotherapy, 2021, 55, 1146-1152.	0.9	5
18	Insulin Allergy. Journal of Pharmacy Technology, 2016, 32, 210-215.	0.5	1

Jennifer D Goldman

#	Article	IF	CITATIONS
19	Advances in Basal Insulin Therapy. Journal of Pharmacy Technology, 2016, 32, 260-268.	0.5	1
20	Nonglycemic Outcomes of Antidiabetic Medications. Clinical Diabetes, 2019, 37, 131-141.	1.2	1
21	Past, Present, and Future Research Avenues for Metformin. Journal of Pharmacy Technology, 2014, 30, 227-234.	0.5	Ο
22	Focus on Hypoglycemia. Nutrition Today, 2015, 50, 277-281.	0.6	0
23	Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. Clinical Diabetes, 2021, 39, 105-116.	1.2	Ο
24	Injection Force Variability: An Overlooked Aspect of Proper Insulin Injection Technique. ADCES in Practice, 2021, 9, 42-47.	0.2	0
25	Linagliptin-Induced Arthralgia. Clinical Diabetes, 2022, 40, 109-112.	1.2	Ο
26	Antihyperglycemic medications for cardiovascular disease risk reduction. American Journal of Managed Care, 2018, 24, S273-S278.	0.8	0
27	Endocrine pharmacotherapy education in United States colleges and schools of pharmacy. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 481-489.	0.5	Ο